Merck & Co. (MRK) - Annual Review 2025

Buy
Rating
$1146
Target Price
79%
Upside

Executive Summary

Merck & Co. continues to demonstrate strong market resilience. Our proprietary Annual Review model indicates robust fundamentals despite macroeconomic headwinds. Key catalysts include product innovation in AI and strategic cost optimization.

Valuation Methodology

We utilize a blended approach of DCF (50%) and EV/EBITDA multiples (50%). Our WACC assumption is 8.1% based on a beta of 1.42.

Risk Factors

Generated by Office Nexus Analytical Engine | 2026-02-19